Barry Callebaut to restart Salmonella-hit plant

Barry Callebaut is to resume production at its factory in Belgium that was involved in a Salmonella contamination incident beginning next month.

Cleaning of the chocolate lines affected by the Salmonella-positive lecithin in the plant in Wieze, is progressing well, said the company.

The first cleaned lines should restart in early August, with a gradual ramp-up to full capacity over the following weeks.

One batch of contaminated lecithin was unloaded at the Wieze factory on June 25. Barry Callebaut confirmed Salmonella Tennessee had been identified in the lecithin system of the factory and in samples of the delivered material. This batch came from a lecithin manufacturer in Hungary and was transported by a third party. The lecithin involved was only used at this site.

The National Food Chain Safety Office (Nébih) in Hungary inspected the lecithin supplier, examining the processing methods, documentation, and taking official samples. Based on follow-up investigations, affected items were not shipped to other companies. Local media named this company as The Vandamme Group.

Blocked before public sale

On June 27, Barry Callebaut detected a Salmonella positive on a production lot manufactured in Wieze and lecithin was identified as the source of the contamination on June 29.

Lecithin is used in all chocolate production lines in Wieze, so the company decided to stop operations and to block all chocolate products manufactured from June 25 to 29, except for cocoa production which is not linked to the lecithin circuit.

On July 1, Barry Callebaut confirmed that, based on its internal investigation, no affected products had entered the retail food chain. No implicated chocolate has been exported by the company outside Europe.

Affected countries include Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Romania, Serbia, Spain, Sweden and the United Kingdom, according to a RASFF alert.

Barry Callebaut informed the Belgian food authority about the incident. The Federal Agency for the Safety of the Food Chain (FASFC) has been to the site as part of an investigation.

(To sign up for a free subscription to Food Safety News, click here.)

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
PICTURES thumbnail

PICTURES

Hier zeigt und beschreibt die Fotostiftung Schweiz Highlights aus ihrer Sammlung Gipsfüsse Alberto Giacometti im Atelier in Paris, um 1960. Ernst Scheidegger / © 2021 Stiftung Ernst Scheidegger-Archiv, / Fotostfitung SchweizDas klassische Künstleratelier ist ein inspirierender Ort: ein Raum, in dem Ideen und Phantasien materielle Gestalt annehmen, von Kreativität durchdrungen und meist voller Spuren, die…
Read More
The healing intersection between astrology and psychology thumbnail

The healing intersection between astrology and psychology

Turning to your birth chart can help you to understand your sensitivity to certain personal dynamics in the world, such as family patterns and romantic interactions. Where did our relationship with our psyche begin? Humans have turned to healers since the dawn of time, and not only for physical ailments. Shamans and spiritual leaders provided…
Read More
The Ghost Research Haunting Nordic Medical Trials thumbnail

The Ghost Research Haunting Nordic Medical Trials

Please enable cookies. Error 1005 Ray ID: 87aca4c0bc60849e • 2024-04-27 06:09:24 UTC What happened? The owner of this website (www.medscape.com) has banned the autonomous system number (ASN) your IP address is in (47583) from accessing this website. Was this page helpful? Thank you for your feedback! Cloudflare Ray ID: 87aca4c0bc60849e • Your IP: 185.124.111.116 •
Read More
Clinical trial confirms immunotherapy drug's efficiency for treating lung cancer thumbnail

Clinical trial confirms immunotherapy drug’s efficiency for treating lung cancer

Credit: Pixabay/CC0 Public Domain Together, the McGill University Health Centre (MUHC), the Centre hospitalier de l'Université de Montréal (CHUM) and St. Mary's Hospital Center (SMHC) have contributed to an international clinical trial that will change the way we treat non-small cell lung cancer (NSCLC)—the most common form of lung cancer. In this trial, an immunotherapy
Read More
Index Of News
Total
0
Share